Evidence map›Paper›PMID 37600518›Full record

ArticleFrontiers in aging neuroscience2023

Leukotriene signaling as molecular correlate for cognitive heterogeneity in aging: an exploratory study.

Heike Mrowetz, Mohamed H Kotob, Jennifer Forster, Iren Aydin, Michael Stefan Unger, Jana Lubec, Ahmed M Hussein, Jovana Malikovic, Daniel Daba Feyissa, Volker Korz and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Heike Mrowetz *Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Mohamed H Kotob *Programme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Jennifer Forster *Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Iren AydinInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Michael Stefan UngerInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Jana LubecProgramme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Ahmed M HusseinProgramme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Jovana MalikovicCore Unit of Biomedical Research, Division of Laboratory Animal Science and Genetics, Medical University of Vienna, Himberg, Austria.
Daniel Daba FeyissaProgramme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Volker KorzProgramme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Harald HögerCore Unit of Biomedical Research, Division of Laboratory Animal Science and Genetics, Medical University of Vienna, Himberg, Austria.
Gert LubecProgramme for Proteomics, Paracelsus Medical University, Salzburg, Austria.
Ludwig AignerInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Paracelsus Medical University · ATMedical University of Vienna · ATAssiut University · EGAustrian Cluster for Tissue Regeneration · ATUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aging is in general associated with a decline in cognitive functions. Looking more closely, there is a huge heterogeneity in the extent of cognitive (dys-)abilities in the aged population. It ranges from the population of resistant, resilient, cognitively unimpaired individuals to patients with severe forms of dementias. Besides the known genetic, environmental and life style factors that shape the cognitive (dys-)abilities in aging, the underlying molecular mechanisms and signals related to cognitive heterogeneity are completely unknown. One putative mechanism underlying cognitive heterogeneity might be neuroinflammation, exerted through microglia, the brain's innate immune cells, as neuroinflammation is central to brain aging and neurodegenerative diseases. Recently, leukotrienes (LTs), i.e., small lipid mediators of inflammation produced by microglia along aging and neurodegeneration, got in the focus of geroscience as they might determine cognitive dysfunctions in aging. Methods: Here, we analyzed the brain's expression of key components of the LT synthesis pathway, i.e., the expression of 5-lipoxygenase (5-Lox), the key enzyme in LT production, and 5-lipoxygenase-activating protein (FLAP) in young and aged rats. More specifically, we used a cohort of rats, which, although grown up and housed under identical conditions, developed into aged cognitively unimpaired and aged cognitively impaired traits. Results: Expression of 5-Lox was increased within the brain of aged rats with the highest levels detected in cognitively impaired animals. The number of microglia cells was higher in the aged compared to the young brains with, again, the highest numbers of 5-Lox expressing microglia in the aged cognitively impaired rats. Remarkably, lower cognitive scores in the aged rats associated with higher numbers of 5-Lox positive microglia in the animals. Similar data were obtained for FLAP, at least in the cortex. Our data indicate elevated levels of the LT system in the brain of cognitively impaired animals. Discussion: We conclude that 5-Lox expressing microglia potentially contribute to the age-related cognitive decline in the brain, while low levels of the LT system might indicate and foster higher cognitive functions and eventually cognitive reserve and resilience in aging.

Indexed as

5-LOXagingcognitionFLAPmicroglia

Identifiers

PMID37600518
PMCPMC10433382
OpenAlexW4385494576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.